Teligene is a high-tech pharmaceutical research and development company established in 2011. Specializing in the creation and industrialization of small molecule innovative drugs, the company's expertise lies in the development of international small molecule targeted anti-tumor drugs. With a seasoned senior technical management team, Teligene is well-versed in the latest drug development technologies and trends both domestically and internationally. In February 2021, the company secured a CNY600.00M Series C investment from ShenZhen GTJA Investment Group. Teligene's primary focus is on designing, screening, optimizing, and developing original small molecule targeted anti-tumor drugs with independent intellectual property rights. The company operates in the Biotechnology, Health Care, and Pharmaceutical industries, with a dedication to innovation and substantial growth potential.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series C | CNY600.00M | 1 | ShenZhen GTJA Investment Group | 24 Feb 2021 |
| Series B | Unknown | 5 |
|
17 Aug 2018 |
No recent news or press coverage available for Teligene.
We care about your data, and we'd love to use cookies make your experience better.
